(IN BRIEF) The Institute of Cancer Research and NEOsphere Biotechnologies have announced a new collaboration to accelerate the discovery of molecular glue degrader drugs, an innovative approach in targeted cancer therapy. The partnership will integrate ICR’s proprietary molecular glue library … Read the full press release
Posted in Business, Education, Healthcare, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged Academic–industry partnership to accelerate rational design of molecular glue degrader drugs for cancer treatment, artificial intelligence, Cancer Drug Discovery, cancer research innovation, Centre for Protein Degradation, computational drug design, E3 ligases, Henrik Daub, high-throughput proteomics, ICR, ICR and NEOsphere Biotechnologies join forces to pioneer systematic discovery of molecular glue degrader therapies, Institute of Cancer Research, Institute of Cancer Research and NEOsphere Biotechnologies partner to advance molecular glue degrader drug discovery, Jonathan Beech, Machine Learning, MGDs, molecular glue degraders, molecular glue library, Monte Rosa Therapeutics, Nature Communications, NEOsphere Biotechnologies, Novartis, proteomics, St Jude Children’s Research Hospital, targeted protein degradation, Zoran Rankovic
(IN BRIEF) Researchers have made a significant breakthrough in cancer drug discovery by identifying a new binding site on the eukaryotic initiation factor 4E (eIF4E), a protein long considered undruggable. The collaborative study between The Institute of Cancer Research (ICR) … Read the full press release
Posted in Healthcare, Pharma & Biotech, Science, Technology, United Kingdom
Tagged anticancer therapies, Astex Pharmaceuticals, breast cancer, Cancer Drug Discovery, Cancer Research UK, cancer treatment, Centre for Cancer Drug Discovery, drug development, druggable binding sites, eIF4E, eIF4G, fragment-based screening, ICR, Institute of Cancer Research, Nature Communications, new drug targets, Olivia Rossanese, Paul Clarke, prostate cancer, protein degradation, protein synthesis, protein synthesis regulation, small molecule inhibitors, therapeutic innovation, undruggable protein
(IN BRIEF) Amsterdam-based LUMICKS has secured €20 million in venture debt from the European Investment Bank (EIB) to advance its next-generation cell avidity platform, which aims to accelerate the development of immunotherapies for cancer treatment. Supported by the InvestEU initiative, … Read the full press release
Posted in Banks, Business, Economy, Environment, Financial, Government, Healthcare, Industrial, Investment, Luxembourg, Management, Netherlands, News, Science, Technology
Tagged Cancer Drug Discovery, EIB, Hugo de Wit, Immunotherapy Tools, investment, LUMICKS, Netherlands, partnership, Robert de Groot, sustainability
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?